Print
Email
Print Edition Stories
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Caliper Life Sciences Inc., a Hopkinton-based provider of life sciences research tools and services, won a $1.8 million Phase 2 task order, through its Caliper Discovery Alliances and Services unit, as part of the Environmental Protection Agency’s ToxCast screening program.
Caliper (Nasdaq: CALP) has worked with the ToxCast program since 2007; the latest funding brings its financing for the in vitro assay database program up to $5.6 million. ToxCast is an EPA-developed program aimed at identifying new ways to identify toxic chemicals. Through the ToxCast screening program, the EPA plans expand screening to other compounds and develop in vitro assays to replace current in vivo tests getting regulatory clearance.
The Phase 2 task order calls for about 700 environmental compounds to be screened using Caliper’s LabChip EZ Reader instrument; The Phase 1 task order screened about 320 compounds.
Caliper tests pharmaceutical drug interactions, using in vitro biochemical assays, with chemicals in the environment, people and animals.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
